Bristol-Myers Squibb Shares Rally on Strong Quarterly Performance

Pharmaceutical giant Bristol-Myers Squibb has demonstrated a remarkable turnaround, with its latest quarterly report exceeding investor expectations through unexpectedly robust financial results and an upgraded annual forecast. The company’s shares surged more than 4% in a single session, breaking free from a prolonged downward trend that had recently pushed them to 52-week lows. This dramatic reversal prompts market observers to question whether this represents a sustainable shift in momentum following months of underperformance.

In a clear display of operational confidence, Bristol-Myers Squibb management has raised its full-year 2025 revenue projection. The company now anticipates generating between $47.5 billion and $48.0 billion, a significant upward revision from its previous guidance range of $46.5 billion to $47.5 billion. Read more...